These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. Menozzi E; Toffoli M; Schapira AHV Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432 [TBL] [Abstract][Full Text] [Related]
10. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146 [TBL] [Abstract][Full Text] [Related]
11. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204 [TBL] [Abstract][Full Text] [Related]
12. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179 [TBL] [Abstract][Full Text] [Related]
13. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sanchez-Martinez A; Beavan M; Gegg ME; Chau KY; Whitworth AJ; Schapira AH Sci Rep; 2016 Aug; 6():31380. PubMed ID: 27539639 [TBL] [Abstract][Full Text] [Related]